Navigation Links
LA BioMed investigator Dr. Christina Wang spearheads study on new male contraceptive gel
Date:6/28/2012

Christina Wang, M.D., lead investigator at Los Angeles Biomedical Research Institute (LA BioMed) one of the leading biomedical research institutes in the country recently completed a study utilizing a new contraceptive gel that has the potential to be developed as a user controlled chemical birth control agent for males. The gel, which contains testosterone and a synthetic progestin called Nestorone, sharply lowers sperm counts in men with few side effects. The study conducted at LA BioMed and the University of Washington is funded by the National Institutes of Child Health and Human Development (NICHD).

Dr. Wang and her team, along with the team at the University of Washington, enrolled 99 men in a preliminary study of the drug combination. One third of them received a gel containing testosterone and a placebo, which was applied for six months. The remaining two thirds received a gel containing testosterone and one of the two concentrations of Nestorone. Fifty-six men completed at least 20 weeks of the study and adhered to the protocol.

The results of the study were reported at the recent Endocrine Society Meeting & Expo in Houston. Of the men receiving the drug combination, 88 to 89 percent achieved a sperm concentration of less than 1 million sperm per milliliter, while those receiving testosterone and the placebo achieved the same low sperm concentration in 23 percent of men. Depending on the dosage, there was a complete absence of sperm in 78 and 69 percent of the men receiving the drug combination, and in 23 percent of the men receiving testosterone and the placebo.

"Up until now, the responsibility for contraception has traditionally always been with the female," said Dr. Wang. "With these new contraceptive methods for males, the responsibility will be shared. While this gel has great potential and minimal side effects, it does warrant further study as a male contraceptive."

Dr. Wang is a renowned andrologist/endocrinologist and a world leader in efforts to develop a safe, effective and reversible hormonal male contraceptive. In addition to this study, she is also working on a Phase I single dose and multiple dose study that tests the safety and tolerability of a new androgen dimethandrolone undecanoate that is being developed as a potential male contraceptive agent by the National Institute of Child Health and Human Development.


'/>"/>

Contact: Diana Soltesz
diana@dsmmedia.com
818-592-6747
Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center (LA BioMed)
Source:Eurekalert

Related medicine news :

1. LA BioMed investigators, Drs. Kevin Bruhn and Noah Craft, develop novel treatment for melanoma
2. UMMS researcher Victor Ambros, Ph.D., named co-recipient of 2012 Janssen Award for Biomedical Research
3. UCSC physicist Alexander Sher named Pew Scholar in the Biomedical Sciences
4. Applied nanobiomedicine: Exploiting nanoparticles to hunt for hidden cancer cells
5. LA BioMeds Dr. Patricia Dickson researching treatments for neurodegenerative disorders
6. LA BioMed receives Grand Challenges Explorations grant
7. Biomedical researchers receive Hartwell Foundation awards
8. LA BioMeds Dr. John Tsuang examines effects of Ibudilast and metamphetamines
9. Leading health care quality expert is 2012 AcademyHealth Distinguished Investigator
10. Damon Runyon Cancer Research Foundation awards $3.3 million to 8 top young clinical investigators
11. Pediatric kidney expert receives Young Investigator Award from American Transplant Congress
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/19/2017)... ... September 19, 2017 , ... The Workgroup for ... health IT to create efficiencies in healthcare information exchange and a trusted advisor to ... their latest industry white paper, entitled Barriers to Adoption of the ERA and ...
(Date:9/19/2017)... ... September 19, 2017 , ... Big ... recognized for its September 2016 donation of dog beds to the K9 officers ... awards and honors for its contribution from city and state officials. , ...
(Date:9/19/2017)... , ... September 19, 2017 , ... Driving Dynamics Inc., ... Training Company by Training Industry Inc. as part of its mission to continually monitor ... Selection to the first annual 2017 Top 20 Health and Safety Training Companies list ...
(Date:9/19/2017)... ... September 19, 2017 , ... The ... annual PAINWeek National Conference. On October 7, at the Hilton Providence, 21 Atwells ... program providing busy clinicians and allied healthcare practitioners with 6.0 hours of relevant, ...
(Date:9/19/2017)... Boca Raton (PRWEB) , ... September 19, 2017 ... ... under the El Naturalista brand, developed by ACPG Laboratories, is coming soon to ... years in Spain, and El Naturalista is a trusted, well-respected brand reliant on ...
Breaking Medicine News(10 mins):
(Date:9/7/2017)...  Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), ... it will be participating in the Morgan Stanley 15 ... Hyatt hotel in New York.  Zimmer Biomet will present ... Time. A live webcast of the presentation ... at http://investor.zimmerbiomet.com .   ...
(Date:9/6/2017)... --  PDI , a leader in infection prevention products ... session focused on the role of chlorhexidine gluconate (CHG) ... 2017 Annual Scientific Meeting of the Association for Vascular ... Phoenix Convention Center in ... also feature PDI,s PrevanticsĀ® Device Swab as ...
(Date:9/5/2017)... Inc. has announced another milestone in their continued growth and success of the ... demands of customer engagements regionally.  ... office is located at 318 West Adams Street, Suite 1528, Chicago, IL ... Xyntek's recently opened Midwest office ... In addition ...
Breaking Medicine Technology: